IL141506A0 - 4,4-biarylpiperidine derivatives with opioid receptor activity - Google Patents

4,4-biarylpiperidine derivatives with opioid receptor activity

Info

Publication number
IL141506A0
IL141506A0 IL14150699A IL14150699A IL141506A0 IL 141506 A0 IL141506 A0 IL 141506A0 IL 14150699 A IL14150699 A IL 14150699A IL 14150699 A IL14150699 A IL 14150699A IL 141506 A0 IL141506 A0 IL 141506A0
Authority
IL
Israel
Prior art keywords
receptor activity
opioid receptor
biarylpiperidine
derivatives
biarylpiperidine derivatives
Prior art date
Application number
IL14150699A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL141506A0 publication Critical patent/IL141506A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL14150699A 1998-09-09 1999-09-06 4,4-biarylpiperidine derivatives with opioid receptor activity IL141506A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9956598P 1998-09-09 1998-09-09
PCT/IB1999/001512 WO2000014066A1 (en) 1998-09-09 1999-09-06 4,4-biarylpiperidine derivatives with opioid receptor activity

Publications (1)

Publication Number Publication Date
IL141506A0 true IL141506A0 (en) 2002-03-10

Family

ID=22275622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14150699A IL141506A0 (en) 1998-09-09 1999-09-06 4,4-biarylpiperidine derivatives with opioid receptor activity

Country Status (41)

Country Link
US (2) US6720336B2 (hr)
EP (1) EP1112255B1 (hr)
JP (1) JP2002524445A (hr)
KR (1) KR20010075024A (hr)
CN (1) CN1316993A (hr)
AP (1) AP2001002088A0 (hr)
AR (1) AR022376A1 (hr)
AT (1) ATE312819T1 (hr)
AU (1) AU749096B2 (hr)
BG (1) BG105411A (hr)
BR (1) BR9913512A (hr)
CA (1) CA2343236C (hr)
CO (1) CO5170416A1 (hr)
CZ (1) CZ2001850A3 (hr)
DE (1) DE69928945T2 (hr)
EA (1) EA200100203A1 (hr)
EE (1) EE200100145A (hr)
ES (1) ES2252960T3 (hr)
GE (1) GEP20033025B (hr)
GT (1) GT199900146A (hr)
HK (1) HK1040396A1 (hr)
HN (1) HN1999000149A (hr)
HR (1) HRP20010167A2 (hr)
HU (1) HUP0103542A3 (hr)
ID (1) ID29129A (hr)
IL (1) IL141506A0 (hr)
IS (1) IS5860A (hr)
MA (1) MA26686A1 (hr)
NO (1) NO20011183L (hr)
NZ (1) NZ509841A (hr)
OA (1) OA11648A (hr)
PA (1) PA8481301A1 (hr)
PE (1) PE20001053A1 (hr)
PL (1) PL346648A1 (hr)
SK (1) SK3032001A3 (hr)
SV (1) SV1999000147A (hr)
TN (1) TNSN99169A1 (hr)
TR (1) TR200100694T2 (hr)
WO (1) WO2000014066A1 (hr)
YU (1) YU11501A (hr)
ZA (1) ZA200101744B (hr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
SE9902765D0 (sv) * 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
EP1279666A1 (en) 2001-07-24 2003-01-29 Pfizer Products Inc. 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands
ES2311711T3 (es) 2002-02-07 2009-02-16 The Curators Of The University Of Missouri Compuestos de 4-(3-hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos como receptores de opioides.
SE0203301D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
NZ539546A (en) 2002-11-26 2007-11-30 Pfizer Prod Inc Phenyl substituted piperidine compounds for use as PPAR activators
DK2368553T3 (en) * 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
AR044010A1 (es) * 2003-04-11 2005-08-24 Janssen Pharmaceutica Nv Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica
WO2005037269A1 (ja) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
WO2005061463A1 (en) 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2006136823A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
DE102005061427A1 (de) * 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxadiazol-Derivate
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
PT2565195E (pt) 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
EP3064503A1 (en) * 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP2240489A1 (en) * 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2263664A1 (en) * 2009-05-18 2010-12-22 Nestec S.A. Opioid receptors stimulating compounds (thymoquinone, Nigella sativa) and food allergy
SG11201906430RA (en) 2017-01-17 2019-08-27 Mebias Discovery Inc Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
US11584765B2 (en) 2017-03-12 2023-02-21 Ecstasy LLC Polycyclic amines as sigma receptor modulators
EP3595661A4 (en) * 2017-03-12 2020-08-19 Xiaodong Wang POLYCYCLIC AMINES USED AS MODULATORS OF OPIOID RECEPTOR
US10172634B1 (en) * 2017-10-16 2019-01-08 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
WO2022006192A1 (en) 2020-07-01 2022-01-06 Ecstasy LLC Polycyclic amines for opioid receptor modulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016280A (en) 1969-07-17 1977-04-05 Byk Gulden Lomberg Chemische Fabrik Gmbh 4,4-Diarylpiperidine compositions and use
DE1936452C3 (de) * 1969-07-17 1975-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenylpiperidlnen
DE2166997C3 (de) 1971-08-04 1980-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
DE2139085C3 (de) * 1971-08-04 1979-01-18 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
DE2139084C3 (de) 1971-08-04 1979-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
ES2066721B1 (es) * 1993-05-18 1996-02-16 Ferrer Int Nuevos compuestos derivados de la piridina 1,4-disustituida.
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
WO1996031208A2 (de) * 1995-04-05 1996-10-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
JP2000506904A (ja) 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
AU737095B2 (en) 1996-05-31 2001-08-09 Nps Pharmaceuticals, Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders

Also Published As

Publication number Publication date
PA8481301A1 (es) 2000-09-29
US6720336B2 (en) 2004-04-13
ID29129A (id) 2001-08-02
ATE312819T1 (de) 2005-12-15
JP2002524445A (ja) 2002-08-06
NO20011183D0 (no) 2001-03-08
DE69928945D1 (de) 2006-01-19
BR9913512A (pt) 2001-06-05
CO5170416A1 (es) 2002-06-27
EP1112255A1 (en) 2001-07-04
AR022376A1 (es) 2002-09-04
CZ2001850A3 (cs) 2001-12-12
GEP20033025B (en) 2003-07-25
HUP0103542A2 (hu) 2002-01-28
HRP20010167A2 (en) 2002-02-28
US20020013321A1 (en) 2002-01-31
EE200100145A (et) 2002-06-17
NZ509841A (en) 2003-08-29
ES2252960T3 (es) 2006-05-16
HN1999000149A (es) 2000-01-12
AU5383799A (en) 2000-03-27
OA11648A (en) 2004-12-08
AP2001002088A0 (en) 2001-03-31
YU11501A (sh) 2003-10-31
CN1316993A (zh) 2001-10-10
EA200100203A1 (ru) 2001-08-27
EP1112255B1 (en) 2005-12-14
SK3032001A3 (en) 2002-04-04
HK1040396A1 (zh) 2002-06-07
BG105411A (bg) 2001-12-29
CA2343236C (en) 2006-01-03
MA26686A1 (fr) 2004-12-20
AU749096B2 (en) 2002-06-20
DE69928945T2 (de) 2006-07-27
ZA200101744B (en) 2002-06-03
PE20001053A1 (es) 2000-10-14
TR200100694T2 (tr) 2001-10-22
PL346648A1 (en) 2002-02-25
SV1999000147A (es) 2000-09-06
HUP0103542A3 (en) 2002-11-28
GT199900146A (es) 2001-02-24
IS5860A (is) 2001-02-23
KR20010075024A (ko) 2001-08-09
WO2000014066A1 (en) 2000-03-16
TNSN99169A1 (fr) 2005-11-10
US20040138220A1 (en) 2004-07-15
NO20011183L (no) 2001-05-04
CA2343236A1 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
IL141506A0 (en) 4,4-biarylpiperidine derivatives with opioid receptor activity
ZA987037B (en) Benzylidene-1-3-dihydro-indol-2-one derivatives having anti-cancer activity.
IL174074A0 (en) Arylpiperazines having activity at the serotonin 1a receptor
GR3036523T3 (en) 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives
PL349504A1 (en) 1,2-annelated quinoline derivatives
HUP0102470A3 (en) 1,3-azole derivatives as retinoid-associated receptor regulators and their use
SG71173A1 (en) 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives
HU9901911D0 (en) Diaza-spiro[3,5]nanone derivatives
EP1084142A4 (en) GPR35A RECEIVER
IL136500A0 (en) 1,4-diazacycloheptane derivatives
AU2574801A (en) Selective iGLUR5 receptor antagonists
ZA200006632B (en) Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity.
HUP9902291A2 (hu) Új 2,3-benzodiazepin-származékok
IL146124A0 (en) 1,5-benzodiazepine derivatives
EP1083909A4 (en) hCEPR RECEPTOR
EP1107774A4 (en) RAMP2a: RECEPTOR ACTIVITY MODIFYING PROTEIN-2a
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
EP1109565A4 (en) GABAB1AA RECEPTOR
GB9910366D0 (en) 1,5-Benzodiazepine Derivatives
GB9813279D0 (en) Modified receptor
GB9825849D0 (en) Receptor
IL165436A0 (en) 7,10-bis-trichlotoacetyl-10 deactylbaccatin III
TW376713U (en) Improved structure for the backrest
GB9807388D0 (en) Teracyclic triterpene derivatives with immunosuppressant activity